GAME CHANGER!! Zydus Unveils ANVIMO - A Revolutionary Drug for Transplant Patients

Zydus Lifesciences has introduced a groundbreaking medication, ANVIMO (Letermovir), designed to prevent Cytomegalovirus (CMV) infections in patients undergoing haematopoietic stem cell transplants (bone marrow transplants) and kidney transplants. Launched on Wednesday, ANVIMO is available in 240 mg and 480 mg dosages, offering a safer and more effective alternative to existing treatments, the company announced in a statement.

CMV infections pose a significant threat to transplant recipients, often resulting in severe complications such as graft failure, reduced survival rates, and extended hospital stays. Conventional treatments like ganciclovir and valganciclovir, while widely used, come with drawbacks including toxicity and bone marrow suppression, which can hinder recovery. In contrast, Letermovir, the active ingredient in ANVIMO, is well-tolerated, exhibits fewer side effects, and provides superior safety, significantly improving outcomes for transplant patients.

Sharvil Patel, Managing Director of Zydus Lifesciences, hailed the launch as a transformative step in transplant care in India. "The introduction of ANVIMO marks a new era in bone marrow and kidney transplant care. By making this critical therapy affordable and accessible, we are reinforcing our commitment to delivering world-class healthcare solutions," Patel said.

In India, transplantation is a vital yet costly procedure, with post-transplant care adding to the financial strain on patients. CMV prophylaxis, in particular, has been a major expense, with imported Letermovir 240 mg previously priced at over Rs 5 lakh per month, rendering it out of reach for many. Zydus has slashed this cost by 91 percent, making ANVIMO a highly affordable option and broadening access to this life-saving treatment.

The launch has been well-received, with Zydus shares rising 1.81 percent to Rs 887.60 per share on the BSE on Wednesday. With ANVIMO, Zydus Lifesciences is poised to revolutionize post-transplant care, offering hope to countless patients across India.